News

Video

Dr Kim on Improving Representation in Clinical Trials

Author(s):

Edward S. Kim, MD, MBA
Conference|International Lung Cancer Congress

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

Edward S. Kim, MD, MBA, physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center, discusses the importance of improving representation in clinical trials.

Related Videos
Benjamin Levy, MD
Paolo Tarantino, MD
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Related Content
Suzanne Lentzsch, MD, PhD, professor, clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons, Columbia University Medical Center and NewYork-Presbyterian Hospital
June 17th 2024

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jing-Zhou Hou, MD, PhD, of UPMC Hillman Cancer Center
June 17th 2024

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center
March 18th 2024

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

Talha Munir, MBChB, PhD, Leeds Teaching Hospital NHS Trust
June 15th 2024

Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies

Uwe Platzbecker, MD, of University Hospital Leipzig
June 15th 2024

ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL